Identifying novel biomarkers for cardiovascular events or death in people with dysglycemia

Circulation

Volumn 132, Issue 24, 2015, Pages 2297-2304

  Gerstein, Hertzel C ^a   Paré, Guillaume ^a   McQueen, Matthew J ^b   Haenel, Heinz ^b   Lee, Shun Fu ^c   Pogue, Janice ^c   Maggioni, Aldo P ^a   Yusuf, Salim ^b   Hess, Sibylle ^c  

^a HAMILTON GENERAL HOSPITAL   (Canada)

^b SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^c ANMCO RESEARCH CENTER   (Italy)

Author keywords

biological markers; clinical trial; diabetes mellitus; risk

Indexed keywords

ALPHA 2 MACROGLOBULIN; AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOPOIETIN 2; APOLIPOPROTEIN B; BIOLOGICAL MARKER; CHROMOGRANIN A; GLUTATHIONE TRANSFERASE ALPHA; GROWTH DIFFERENTIATION FACTOR 15; MACROPHAGE DERIVED CHEMOKINE; OSTEOPROTEGERIN; SCATTER FACTOR RECEPTOR; SELENOPROTEIN P; SOMATOMEDIN BINDING PROTEIN 2; SOMATOMEDIN BINDING PROTEIN 4; TENASCIN; TREFOIL FACTOR 3; UNCLASSIFIED DRUG; GLUCOSE BLOOD LEVEL;

ADULT; ARTICLE; BLOOD BANK; CARDIOMETABOLIC RISK; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; DYSGLYCEMIA; FEMALE; FOLLOW UP; HEART FAILURE; HEART INFARCTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; REVASCULARIZATION; AGED; BLOOD; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; CONTROLLED STUDY; DIABETES MELLITUS, TYPE 2; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; MORTALITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TRENDS;

AGED; BIOMARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CAUSE OF DEATH; DIABETES MELLITUS, TYPE 2; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK FACTORS;

EID: 84952630366     PISSN: 00097322     EISSN: 15244539     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.115.015744     Document Type: Article

References (31)

1. Seshasai SR, Kaptoge S, Thompson A, Di AE, Gao P, Sarwar N, Whincup PH, Mukamal KJ, Gillum RF, Holme I, Njolstad I, Fletcher A, Nilsson P, Lewington S, Collins R, Gudnason V, Thompson SG, Sattar N, Selvin E, Hu FB, Danesh J. Diabetes mellitus, fasting glucose, and risk of causespecific death. N Engl J Med. 2011;364:829-841
2. Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with nondiabetic people: a population-based retrospective cohort study. Lancet. 2006;368:29-36. doi: 10.1016/S0140-6736(06)68967-8
3. Anand SS, Dagenais GR, Mohan V, Diaz R, Probstfield J, Freeman R, Shaw J, Lanas F, Avezum A, Budaj A, Jung H, Desai D, Bosch J, Yusuf S, Gerstein HC; EpiDREAM Investigators. Glucose levels are associated with cardiovascular disease and death in an international cohort of normal glycaemic and dysglycaemic men and women: the EpiDREAM cohort study. Eur J Prev Cardiol. 2012;19:755-764. doi: 10.1177/1741826711409327
4. Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF. Lifetime risk for diabetes mellitus in the United States. JAMA. 2003;290:1884-1890. doi: 10.1001/jama.290.14.1884
5. Gregg EW, Cheng YJ, Saydah S, Cowie C, Garfield S, Geiss L, Barker L. Trends in death rates among U.S. adults with and without diabetes between 1997 and 2006: findings from the National Health Interview Survey. Diabetes Care. 2012;35:1252-1257. doi: 10.2337/dc11-1162
6. Gregg EW, Li Y, Wang J, Burrows NR, Ali MK, Rolka D, Williams DE, Geiss L. Changes in diabetes-related complications in the United States, 1990-2010. N Engl J Med. 2014;370:1514-1523. doi: 10.1056/NEJMoa1310799
7. Gerstein HC, Werstuck GH. Dysglycaemia, vasculopenia, and the chronic consequences of diabetes. Lancet Diabetes Endocrinol. 2013;1:71-78. doi: 10.1016/S2213-8587(13)70025-1
8. Yin X, Subramanian S, Hwang SJ, ODonnell CJ, Fox CS, Courchesne P, Muntendam P, Gordon N, Adourian A, Juhasz P, Larson MG, Levy D. Protein biomarkers of new-onset cardiovascular disease: prospective study from the systems approach to biomarker research in cardiovascular disease initiative. Arterioscler Thromb Vasc Biol. 2014;34:939-945. doi: 10.1161/ATVBAHA.113.302918
9. Origin Trial Investigators. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008;155:26-32
10. Bosch J, Gerstein HC, Dagenais GR, Daz R, Dyal L, Jung H, Maggiono AP, Probstfield J, Ramachandran A, Riddle MC, Rydn LE, Yusuf S; ORIGIN Trial Investigators. n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia. N Engl J Med. 2012;367:309-318. doi: 10.1056/NEJMoa1203859
11. Hlatky MA, Greenland P, Arnett DK, Ballantyne CM, Criqui MH, Elkind MS, Go AS, Harrell FE Jr, Hong Y, Howard BV, Howard VJ, Hsue PY, Kramer CM, McConnell JP, Normand SL, ODonnell CJ, Smith SC Jr, Wilson PW; American Heart Association Expert Panel on Subclinical Atherosclerotic Diseases and Emerging Risk Factors and the Stroke Council. Criteria for evaluation of novel markers of cardiovascular risk: a scientific statement from the American Heart Association. Circulation. 2009;119:2408-2416. doi: 10.1161/CIRCULATIONAHA.109.192278
12. McGorrian C, Yusuf S, Islam S, Jung H, Rangarajan S, Avezum A, Prabhakaran D, Almahmeed W, Rumboldt Z, Budaj A, Dans AL, Gerstein HC, Teo K, Anand SS; INTERHEART Investigators. Estimating modifiable coronary heart disease risk in multiple regions of the world: the INTERHEART Modifiable Risk Score. Eur Heart J. 2011;32:581-589. doi: 10.1093/eurheartj/ehq448
13. Cook NR, Ridker PM. Advances in measuring the effect of individual predictors of cardiovascular risk: the role of reclassification measures. Ann Intern Med. 2009;150:795-802
14. Steyerberg EW, Vickers AJ, Cook NR, Gerds T, Gonen M, Obuchowski N, Pencina MJ, Kattan MW. Assessing the performance of prediction models: a framework for traditional and novel measures. Epidemiology. 2010;21:128-138. doi: 10.1097/EDE.0b013e3181c30fb2
15. Pencina KM, Pencina MJ, DAgostino RB Sr. What to expect from net reclassification improvement with three categories. Stat Med. 2014;33:4975-4987. doi: 10.1002/sim.6286
16. Pencina MJ, DAgostino RB Sr, DAgostino RB Jr, Vasan RS. Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond. Stat Med. 2008;27:157-172; discussion 207. doi: 10.1002/sim.2929
17. Harrell FE Jr, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med. 1996;15:361-387. doi: 10.1002/(SICI)1097-0258(19960229)15:43.0.CO;2-4
18. Wu YC, Lee WC. Alternative performance measures for prediction models. PLoS One. 2014;9:e91249. doi: 10.1371/journal.pone.0091249
19. Walter SD, Sinuff T. Studies reporting ROC curves of diagnostic and prediction data can be incorporated into meta-Analyses using corresponding odds ratios. J Clin Epidemiol. 2007;60:530-534. doi: 10.1016/j.jclinepi.2006.09.002
20. Daniels LB, Maisel AS. Natriuretic peptides. J Am Coll Cardiol. 2007;50:2357-2368. doi: 10.1016/j.jacc.2007.09.021
21. Hillis GS, Welsh P, Chalmers J, Perkovic V, Chow CK, Li Q, Jun M, Neal B, Zoungas S, Poulter N, Mancia G, Williams B, Sattar N, Woodward M. The relative and combined ability of high-sensitivity cardiac troponin T and N-terminal pro-B-type natriuretic peptide to predict cardiovascular events and death in patients with type 2 diabetes. Diabetes Care. 2014;37:295-303. doi: 10.2337/dc13-1165
22. Matsushita K, Sang Y, Ballew SH, Astor BC, Hoogeveen RC, Solomon SD, Ballantyne CM, Woodward M, Coresh J. Cardiac and kidney markers for cardiovascular prediction in individuals with chronic kidney disease: the Atherosclerosis Risk in Communities study. Arterioscler Thromb Vasc Biol. 2014;34:1770-1777. doi: 10.1161/ATVBAHA.114.303465
23. Wei G, Yaqi R, Ningfu W, Xuwei H. N-terminal prohormone B-type natriuretic peptide and cardiovascular risk in stable coronary artery disease: a meta-Analysis of nine prospective studies. Rev Cardiovasc Med. 2013;14:e92-e98
24. Eklund L, Saharinen P. Angiopoietin signaling in the vasculature. Exp Cell Res. 2013;319:1271-1280. doi: 10.1016/j.yexcr.2013.03.011
25. Ahmed A, Fujisawa T. Multiple roles of angiopoietins in atherogenesis. Curr Opin Lipidol. 2011;22:380-385. doi: 10.1097/MOL.0b013e32834b26b3
26. Anuradha S, Mohan V, Gokulakrishnan K, Dixit M. Angiopoietin-2 levels in glucose intolerance, hypertension, and metabolic syndrome in Asian Indians (Chennai Urban Rural Epidemiology Study-74). Metabolism. 2010;59:774-779. doi: 10.1016/j.metabol.2009.09.022
27. Lorbeer R, Baumeister SE, Drr M, Nauck M, Grotevendt A, Vlzke H, Vasan RS, Wallaschofski H, Lieb W. Circulating angiopoietin-2, its soluble receptor Tie-2, and mortality in the general population. Eur J Heart Fail. 2013;15:1327-1334. doi: 10.1093/eurjhf/hft117
28. Lieb W, Zachariah JP, Xanthakis V, Safa R, Chen MH, Sullivan LM, Larson MG, Smith HM, Yang Q, Mitchell GF, Vita JA, Sawyer DB, Vasan RS. Clinical and genetic correlates of circulating angiopoietin-2 and soluble Tie-2 in the community. Circ Cardiovasc Genet. 2010;3:300-306. doi: 10.1161/CIRCGENETICS.109.914556
29. Habig WH, Pabst MJ, Jakoby WB. Glutathione S-transferases: the first enzymatic step in mercapturic acid formation. J Biol Chem. 1974;249:7130-7139
30. Curtis JM, Grimsrud PA, Wright WS, Xu X, Foncea RE, Graham DW, Brestoff JR, Wiczer BM, Ilkayeva O, Cianflone K, Muoio DE, Arriaga EA, Bernlohr DA. Downregulation of adipose glutathione S-transferase A4 leads to increased protein carbonylation, oxidative stress, and mitochondrial dysfunction. Diabetes. 2010;59:1132-1142. doi: 10.2337/db09-1105
31. Franco R, Schoneveld OJ, Pappa A, Panayiotidis MI. The central role of glutathione in the pathophysiology of human diseases. Arch Physiol Biochem. 2007;113:234-258. doi: 10.1080/13813450701661198